Financial Review: Decoy Therapeutics (NASDAQ:DCOY) & AB Corporate Bond ETF (NASDAQ:EYEG)

Decoy Therapeutics (NASDAQ:DCOY) and AB Corporate Bond ETF (NASDAQ:EYEG) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Decoy Therapeutics and AB Corporate Bond ETF, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1	0	1	0	2.00
AB Corporate Bond ETF	0	0	0	0	0.00

Decoy Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 702.14%. Given Decoy Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Decoy Therapeutics is more favorable than AB Corporate Bond ETF.

Insider & Institutional Ownership

11.9% of Decoy Therapeutics shares are held by institutional investors. Comparatively, 64.2% of AB Corporate Bond ETF shares are held by institutional investors. 1.7% of Decoy Therapeutics shares are held by insiders. Comparatively, 58.2% of AB Corporate Bond ETF shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Decoy Therapeutics has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, AB Corporate Bond ETF has a beta of 0.17, indicating that its share price is 83% less volatile than the S&P 500.

Profitability

This table compares Decoy Therapeutics and AB Corporate Bond ETF’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-395.42%	-193.30%
AB Corporate Bond ETF	N/A	-104.96%	-60.03%

Valuation and Earnings

This table compares Decoy Therapeutics and AB Corporate Bond ETF”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52 million	($106.90)	-0.03
AB Corporate Bond ETF	$12,059.00	2,297.37	-$8.09 million	($1.68)	-20.61

AB Corporate Bond ETF has higher revenue and earnings than Decoy Therapeutics. AB Corporate Bond ETF is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

AB Corporate Bond ETF beats Decoy Therapeutics on 7 of the 12 factors compared between the two stocks.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

About AB Corporate Bond ETF

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.